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Objective: Examine time to recurrence of major depressive disorder (MDD) across different treatment
settings and assess predictors of time to recurrence of MDD.
Methods: Data were from 375 subjects with a MDD diagnosis from the Netherlands Study of Depression
and Anxiety (NESDA). The study sample was restricted to subjects with a remission of at least three
months. These subjects were followed until recurrence or the end of the two year follow-up. DSM-IV
based diagnostic interviews and Life Chart Interviews were used to assess time to recurrence of MDD
across treatment settings. Predictors of time to recurrence were determined using Cox’s proportional
hazards analyses.
Results: Although trends indicated a slightly higher rate of and shorter time to recurrence in specialized
mental health care, no signiﬁcant difference in recurrence rate (26.8% versus 33.5%, p¼0.23) or in time
to recurrence (controlled for covariates) of MDD was found between respondents in specialized mental
health care and respondents treated in primary care (average 6.6 versus 5.5 months, p¼0.09). In
multivariable analyses, a family history of MDD and previous major depressive episodes were
associated with a shorter time to recurrence. Predictors did not differ across treatment settings.
Limitations: The study sample may not be representative of the entire population treated for MDD in
specialized mental health care.
Conclusions: Health care professionals in both settings should be aware of the same risk factors since
the recurrence risk and its predictors appeared to be similar across settings.
& 2012 Elsevier B.V. All rights reserved.1. Introduction
Major depressive disorder (MDD) is among the leading causes
of disability worldwide. This is largely due to its highly chronic
and recurrent nature (Murray and Lopez, 1997; Vos et al., 2004).
The risk of recurrence after a ﬁrst major depressive episode is 50%
and increases with subsequent episodes (Post, 1992; Kupfer et al.,
1996; American Psychiatric Association, 2000). Efforts to reduce
the disabling effects of depression should be expanded with
recurrence prevention strategies, especially in patients at high
risk of recurrence (Bockting et al., 2011). Strategies to prevent
recurrence of a major depressive episode can be highly effective.
A meta-analysis found a number needed to treat (NNT) of ﬁvell rights reserved.
0 RR, Ede, The Netherlands.
rdeveld).(Hansen et al., 2008). In comparison, the number needed to treat to
prevent one major cerebrovascular event with aspirin over a mean
follow-up of 6.9 years is 253 (Berger et al., 2011). However, knowl-
edge of recurrence risk of MDD is incomplete (Hardeveld et al.,
2010). It is still difﬁcult to identify high risk groups, and data on
MDD recurrence risk is mainly based on studies performed in
specialized mental health care. It is important to understand the
extent to which this information can be generalized to patients in
primary care settings, where the majority of people with MDD are
treated. If the risk of recurrence in MDD patients treated in primary
care differs from those in specialized mental health care, different
recommendations for prevention of recurrence are needed. This
knowledge might facilitate further improvements in the quality and
cost-effectiveness of depression management.
We expect the risk of recurrence of MDD to be higher in
specialized mental health care than that in primary care since
those with the most severe, complex, recurrent and long-lasting
disorders are more often treated in specialized mental health care
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hypothesis is not well documented, mainly because data on the
risk of recurrence among MDD patients in primary care settings
are scarce (Gilchrist and Gunn, 2007; Hardeveld et al., 2010) and,
in particular, prospective longitudinal studies are lacking.
Furthermore, it is important to be aware of the predictors of
recurrence of MDD. This knowledge would make it possible to
identify patients with a high risk for recurrence. Predictors of
recurrence of MDD might be different across treatment settings.
The studies available to date, which have aimed to identify risk
factors for recurrence, have largely been carried out in specialized
mental health care. The results suggest that subclinical residual
symptoms and the number of previous episodes are the most
important predictors for recurrence of MDD, whereas demo-
graphic factors are not related to recurrence of MDD (Hardeveld
et al., 2010). To our knowledge, a study on risk factors for (time to)
recurrence among patients treated in the specialized mental health
care as well as those in primary care—also allowing a direct com-
parison—has not been done.
The aim of this study was therefore to examine the time to
recurrence of MDD and its predictors among subjects who recovered
from their last episode of MDD, and compare the ﬁndings between
primary care and specialized mental health care.2. Methods
2.1. Study sample
Data were from the Netherlands Study of Depression and Anxiety
(NESDA), an ongoing longitudinal cohort study, which began in
2004, and examines the long-term course of depressive and anxiety
disorders in different health care settings. The study protocol was
approved centrally by the Ethical Review Board of the VU University
Medical Centre, and subsequently by local review boards of each
participating centre. All respondents provided informed consent. For
the present study, data from the ﬁrst two years of follow-up were
used. The rationale, objectives, and methods of NESDA have been
described in detail elsewhere (Penninx et al., 2008). In brief, the
NESDA cohort (N¼2981) consists of respondents (18–65 years) with
(i) a current anxiety and/or depressive disorder, (ii) a prior history of
a depressive and/or anxiety disorder and (iii) healthy controls. All
respondents were administered a baseline assessment, which
included evaluation of psychopathology, demographic and personal
characteristics, psychosocial functioning, and biomarkers. Respon-
dents were recruited in primary care through a screening procedure,
in specialized mental health care when newly enroled, and in the
community. Respondents with a primary diagnosis of a psychotic
disorder, obsessive-compulsive disorder, bipolar disorder, a severe
addiction disorder, or who were not ﬂuent in Dutch were excluded.
For our study sample, the classiﬁcation of treatment settings
(primary care versus specialized mental health care) was based on
the recruitment setting but this was also conﬁrmed with data from
the Trimbos/iMTA questionnaire for Costs associated with Psychia-
tric Illness (TIC-P) (Hakkaart-van Roijen, 2002). The TIC-P is a fully
structured interview that assesses loss of productivity, health care
utilization, and costs. Respondents were asked whether they had
sought help for mental problems within the past six months. Those
who had not sought help were not included because we wanted to
compare respondents treated in specialized mental health care with
those treated in primary care. Respondents were considered to be
under treatment in specialized mental health care or primary care if
they had at least two contacts in the six months prior to the baseline
interview. The sources of care included primary care (general
practitioner, ﬁrst line psychologist, social worker, social psychiatric
nurse) and specialized mental health care (ambulatory mentalhealth care including a psychiatrist/psychotherapist working in
private practice and residential mental health care).
Diagnoses of MDD were based on the Composite International
Diagnostic Interview (CIDI), Lifetime Version 2.1 (WHO Lifetime
Version 2.1). The CIDI is a structured interview developed by the
World Health Organization (1997) and has been found to have high
inter-rater reliability (Wittchen, 1994), high test-retest reliability
(Wacker et al., 2006), and satisfactory validity for depressive and
anxiety disorders (Wittchen et al., 1989; Wittchen, 1994).
The study sample was restricted to subjects with a MDD
diagnosis in the six months prior to baseline assessment, who were
symptomatic in the month prior to baseline, and achieved remission
during the two-year follow-up. In this way we tried to select a large
sample of respondents who also had aMDD at baseline. Accordingly,
the sample was limited to 706 subjects with a MDD diagnosis who
conﬁrmed symptoms in the month prior to baseline either through
the CIDI recency questions or the Life Chart Interview (LCI) (Lyketsos
et al., 1994) and who sought help for their MDD. Of these subjects,
566 (80.2%) participated in the two-year follow-up, of which a
further six respondents were excluded because they did not have a
(complete) LCI during follow-up. Drop-out was associated with
lower educational attainment (p¼0.01), but not with gender, age,
severity of the last major depressive episode (MDE) or number of
previous episodes of MDD. A further 142 respondents were excluded
because they did not achieve remission from MDD within the two-
year follow-up. Remission was deﬁned as a reduction of symptoms
to no or minimal severity for at least three consecutive months
using the LCI. This three-month criterion is in line with previous
research (Spijker et al., 2002). During follow-up the percentage of
respondents achieving remission was not statistically signiﬁcant
(19.0% in primary care versus 24.0% in specialized mental health
care, chi-square¼1.33, df¼1, p¼0.25). Finally, 43 respondents were
excluded because the diagnosis was changed to bipolar disorder
during follow-up. So, the sample ‘at risk’ for a recurrence of MDD
consisted of 375 respondents. Of those recruited from the commu-
nity, 21 respondents were treated in specialized mental health care
and twelve in primary care after checking data from the TIC-P.
Furthermore, 29 respondents which were recruited in primary care
were treated in specialized mental health care. As a consequence, 97
were treated in primary care (25.9%) and 278 (74.1%) were treated
in specialized mental health care. A ﬂow-chart is displayed in Fig. 1.
2.2. Time to recurrence
Time to recurrence was assessed prospectively during the two-
year follow-up using the LCI. For each month with reported
symptoms, severity was assessed (no or minimal severity, mild,
moderate, severe, or very severe). Recurrence was operationalized as
a return of symptoms after remission to at least mild severity level
persisting for at least one month with the additional criterion that a
CIDI-conﬁrmed MDD diagnosis was present during follow-up.
2.3. Determinants of time to recurrence
The following variables that we considered relevant as deter-
minant of time to recurrence or as covariate and were assessed at
baseline with several semi-structured questionnaires.
2.3.1. Socio-demographic factors
Gender, age, and level of educational attainment (in years of
education).
2.3.2. Clinical factors
Using the CIDI, the following information was obtained: age
of onset of MDD, severity of the MDE in the month preceding
Baseline population (n = 2981)
Study population at baseline (n = 706)
Excluded:
- No MDD at baseline (n = 2137)
- No treatment (n = 138)
Study cohort (n = 375)
Excluded:
- drop-out (n = 140)
- no life chart interview coverage (n = 6)
- no remission of MDD (n = 142)
- diagnosis changed to bipolar  
disorder (n = 43)
Primary care
(n = 97)
Specialized mental 
health care (n = 278)
Fig. 1. Flow chart of selection process for study population.
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ized into mild, moderate and severe), and lifetime number of MDEs
categorized into single or recurrent. Information on the duration of
symptoms prior to baseline was derived from the baseline LCI that
assessed the percentage of time the respondent spent with depres-
sive symptoms in the previous year. History of depression in ﬁrst-
degree family members was assessed using a family tree inventory
(Fyer and Weissman, 1999), categorized into yes or no. The
comorbid disorders that we deemed relevant were lifetime alcohol
abuse/dependence or any anxiety disorder (panic disorder, social
phobia, generalized anxiety disorder, agoraphobia) within the six
months before baseline. Comorbidity with somatic illnesses was
assessed by means of a questionnaire listing 20 mostly chronic
disorders for which the respondent was treated.
2.3.3. Psychosocial factors
Neuroticism was measured with the twelve-item subscale of the
NEO Five-Factor Inventory (NEO-FFI) Questionnaire ranging from 0
(low neuroticism) to 48 (high neuroticism) (Costa and McCrae, 1995).
Negative life events in the last year were determined with the Brugha
questionnaire ranging from 0 to 5 (Brugha et al., 1985) and included
12 speciﬁc events and one ‘other’ category asking about other serious
negative life events. In order to examine the role of childhood trauma,
a cumulative childhood index using the NEMESIS childhood trauma
interview was constructed (De Graaf et al., 2002; Wiersma et al.,
2009; Hovens et al., 2010). Participants were asked four questions
regarding childhood experiences of emotional neglect, or emotional,
physical, or sexual abuse. The cumulative index was calculated for
each participant as the sum of the number and frequency of the four
types of abuse (range, 0–8).
2.3.4. Treatment
Respondents were asked about the type of treatment they had
received for their MDD, subdivided into pharmacological treat-
ment and psychological treatment. Pharmacological treatment
was assessed based on inspection of the medication boxes used in the
past month and coded using the WHO Anatomical Therapeutic
Chemical (ATC) classiﬁcation (REF to URL). Use of antidepressants
was taken into account when the medication was taken at least 50%
of the time and included selective serotonin reuptake inhibitors
(ATC-code N06AB), tricyclic antidepressants (N06AA) or other anti-
depressants (N06AF/N06AX). The receipt of psychological treatment
(psychotherapy, counselling, and skills training) was based on self-
report.
2.4. Statistical methods
For the analyses, SPSS for Windows Version 17.0 (SPSS Inc.,
USA) was used. Descriptives across treatment setting(primary care, specialized mental health care) were compared
using independent t-tests for continuous variables and chi-square
tests for categorical variables. A two-tailed pr0.05 was consid-
ered statistically signiﬁcant. We used Kaplan–Meier survival
curves to estimate the time to recurrence of MDD during
follow-up across treatment settings. Subjects who—at the end
of the follow-up period—did not meet the criteria for the end-
point event (recurrence) were censored. Subsequently, we studied
possible predictors of recurrence of MDD (including treatment
setting) using Cox’s proportional hazards analyses. Predictors that
had a p-value r0.20 in the univariable analyses were included in
multivariable analyses in which the forced entry method was
used. Time to recurrence of MDD (yes/no) during the two-year
follow-up was the main outcome measure. Because the number of
subjects treated in primary care was relatively small (n¼97) we
could not make a separate comparison of the predictors of
recurrence between settings. Instead, we added a setting by
predictor interaction term to check whether possible differences
in recurrence risk between treatment settings were explained by
differences in predictors.3. Results
3.1. Characteristics
Themean age of the study sample was 40.3 years, and 66.9% were
female. The socio-demographic, clinical and treatment variables are
shown by setting in Table 1. Respondents treated in specialized
mental health care were younger, had a younger age of onset, had a
higher neuroticism score and a higher percentage had psychological
treatment and/or medication (po0.05). Table 2 describes the course
characteristics of MDD during follow-up. Percentage of recurrence,
mean and average time to recurrence and average duration of follow-
up did not differ signiﬁcantly between treatment settings.
3.2. Recurrence risk
During the two-year follow-up, 26.8% (n¼26) of respondents
in primary care and 33.5% (n¼93) treated in specialized mental
health care experienced a recurrence of MDD after having
achieved remission for at least three months (chi-square¼1.47,
df¼1, p¼0.23) (see inclusion criteria). Fig. 2 shows the survival
curve of MDD recurrence across different settings. The slope of
the survival curve suggests that the risk of recurrence is highest in
the ﬁrst months after recovery, regardless of treatment setting.
There was no signiﬁcant difference in time to recurrence of
MDD between respondents in specialized mental health care in
Table 1
Characteristics of 375 subjects at risk for a recurrence of MDD from the NESDA study by treatment setting.
Primary care (n¼97) Specialized mental health care (n¼278) p*
Socio-demographic factors
Gender (% female) 70.1 65.8 0.44
Age (mean yrs, sd) 43.9 (12.1) 39.1 (11.7) o0.01
Educational attainment ( mean yrs, sd) 11.5 (3.1) 11.4 (3.0) 0.75
Clinical factors
Age of onset (mean yrs, sd) 30.4 (14.0) 27.1 (12.5) 0.03
Family history of depression (%) 87.6 85.6 0.62
Severity of the last MDE (CIDI) Mild 38.1 27.3 0.13
Moderate 28.9 31.7
Severe 33.0 41.0
Recurrent MDD (%) 53.8 51.1 0.66
Percentage months with symptoms of MDD in past year (mean, sd) 0.6 (0.4) 0.7 (0.3) 0.08
Anxiety disorder (any, 6 months) 59.8 68.0 0.14
Alcohol abuse/dependence (lifetime) 37.1 29.5 0.16
Number chronic somatic illness (mean number, sd) 0.8 (1.2) 0.6 (0.9) 0.12
Psychosocial factors
Trauma before age 16 (mean score, sd) 1.0 (1.2) 1.3 (1.2) 0.07
Negative life events (mean, sd) 1.2 (1.36) 0.9 (1.09) 0.06
Neuroticism (mean score, sd) 29.0 (6.6) 31.1 (6.5) o0.01
Treatment
Pharmacological treatment (% yes) 49.5 65.1 o0.01
Psychological treatment (% yes) 45.4 63.3 o0.01
n p-value based on chi-square statistics for categorical variables and independent t-test for continuous variables. In bold: statistically signiﬁcant.
Table 2
Course characteristics of 375 respondents at risk for a recurrence of MDD from
NESDA by setting.
Primary
care
Specialized mental
health care
p*
Percentage of recurrence (%) 26.8 33.5 0.23
Average time to recurrence
(months)
6.6 5.6 0.30
Median time to recurrence
(months)
5.5 5.0 0.30
Average duration of follow-up
(months)
15.3 14.1 0.21
n Pearson Chi-square and Mann–Whitney U test used, uncontrolled for
covariates.
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CI¼0.86–2.05, p¼0.21). When controlled for socio-demographic,
clinical, psychosocial and treatment factors, time to recurrence
did not differ signiﬁcantly, but a trend was found towards a
shorter time to recurrence in specialized mental health care
(HR¼1.52, 95% CI¼0.93–2.48, p¼0.09). Table 3 shows the poten-
tial risk factors of time to recurrence of MDD using both univari-
able and multivariable Cox proportional regression analyses.
Analyses showed that the presence of a family history of depres-
sion and having a previous MDE were associated with a shorter
time to recurrence of MDD. In multivariable analyses, the pre-
sence of a family history of depression (HR¼2.12, 95%CI¼1.07–
4.22, p¼0.03) and having a previous MDE (HR¼1.59, 95%
CI¼1.08–2.35, p¼0.02) remained signiﬁcant predictors of time
to recurrence. Finally, no signiﬁcant interaction terms were found
for treatment setting by predictor, implying that predictors of
time to recurrence did not differ across treatment settings.4. Discussion
To our knowledge, this is the ﬁrst prospective naturalistic
cohort study to directly compare the recurrence risk and pre-
dictors of time to recurrence in subjects with a MDD diagnosis
across different treatment settings. The results indicate that thetime to recurrence during the two-year follow-up did not differ
between patients treated in primary care and in specialized
mental health care. Given the presence of more severe, more
treatment resistant, chronic and more complex patients in spe-
cialized mental health care, one might expect that the risk of
recurrence would be higher in this care setting. However, our
ﬁndings are in line with previous studies carried out in primary
care (Lin et al., 1998; Gopinath et al., 2007; Vuorilehto et al.,
2009; Suija et al., 2011). In a study performed in primary care
among 386 respondents (Gopinath et al., 2007), 31.1% of patients
had a recurrence after one year. Similar results were found in a
study by Lin et al. (1998) (37.1% after one year), Vuorilehto et al.
(2009) (27% after 15 months) and Suija et al. (2011) who observed
a recurrence percentage of 28% after one year. In comparison, in
specialized mental health care the percentage of MDD recurrence
after one year ranges from 21% to 37% (Kanai et al., 2003; Maj
et al., 1992; Hardeveld et al., 2010). Although remaining non-
signiﬁcant, a trend towards a shorter time to recurrence in
specialized mental health care was noticeable (HR¼1.52, 95%
CI¼0.93–2.48, p¼0.09) and the hazard ratio increased from 1.32
to 1.52 when corrected for all covariates, suggesting that the risk
of recurrence increases in secondary care in comparison with
primary care and was confounded by these variables. A possible
explanation for the similar recurrence risk found across treatment
settings is that the distribution of risk factors for MDD recurrence
does not differ much between treatment settings. Previous
research, also performed with NESDA data (Piek et al., 2011),
found that patients were more likely to be referred to secondary
care if they were younger, reported suicidal symptoms, had
chronic depression, or were referred for psychotherapy. It seems
that factors related to referral to specialized mental health care, in
general, differ from predictors of recurrence. It could be that the
decision to refer to specialized mental health care is determined
to a greater exent by the need for acute treatment of MDD or the
preferences of the patient than by expectations of a protracted
course. When we excluded those who did not recover from a MDE
during follow-up, respondents who were younger, had an earlier
age of onset and a higher neuroticism score were most likely to be
referred and treated in specialized mental health care. Although
these could be risk factors for recurrence, our study found that the
Fig. 2. Survival curve of time to recurrence of MDE across different settings in a cohort from NESDA.
Table 3
Univariable and multivariable analyses of potential predictors of time to recurrence of MDE in a cohort from NESDA (n¼375).
Time to recurrence
Univariable analyses Multivariable analyses*
HR 95% CI p HR 95% CI p
Socio-demographic factors
Gender, female 1.43 0.95–2.16 0.09 1.42 0.92–2.20 0.11
Age (yrs) 0.99 0.97–1.00 0.13 0.99 0.97–1.01 0.33
Educational attainment (yrs) 1.03 0.97–1.10 0.29
Clinical factors
Age of onset (yrs) 0.99 0.98–1.0 0.11 1.00 0.98–1.02 0.80
Family history of depression Yes 2.16 1.09–4.26 0.03 2.12 1.07–4.22 0.03
Severity of the last MDE Mild 1 – –
Moderate 0.95 0.60–1.52 0.84
Severe 1.11 0.72–1.72 0.63
Recurrent MDD (% recurrent) 1.61 1.10–2.35 0.01 1.59 1.08–2.35 0.02
Percentage months with symptoms of MDD in past year 0.87 0.53–1.50 0.60
Anxiety disorder (any) Yes 0.90 0.62–1.31 0.60
Alcohol abuse/dependence Yes 0.88 0.59–1.30 0.51
Number chronic somatic illnesses High 1.05 0.88–1.24 0.61
Psychosocial
Trauma before age 16 High 1.10 0.95–1.26 0.22
Life events Low 1.02 0.87–1.19 0.81
Neuroticism High 1.00 0.97–1.03 0.93
Treatment
Pharmacological treatment No 1.29 0.90–1.86 0.16 1.16 0.80–1.68 0.43
Psychological treatment No 1.64 0.81–1.67 0.41
Setting
Specialized mental health care 1.32 0.86–2.05 0.21
n Forced entry method used if in univariable analyses pr0.20. In bold: statistically signiﬁcant.
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of recurrent MDEs and the presence of a family history of
depression. These factors did not differ across treatment settings.
An alternative explanation may be that those referred to specia-
lized care receive more intensive treatment for recurrence pre-
vention and that this reduced recurrence rate to a similar level as
was found in primary care.As mentioned earlier, our study found that a history of recurrent
MDD and the presence of a family history of depression predicted a
shorter time to recurrence. Previous research also found these
predictors to be related to recurrence of MDD (Maj et al., 1992;
Mueller et al., 1999; Solomon et al., 2000). Family history of MDD,
which had the highest hazard ratio for recurrence, is of special
interest, because this might indicate an important genetic
F. Hardeveld et al. / Journal of Affective Disorders 147 (2013) 225–231230vulnerability for (the recurrence of) MDD. Further studies should
examine this genetic basis, preferably prospectively, and should
focus on predictors of recurrence early in the lifetime course. These
studies should also take into account the interactions between
genetic, biological, environmental, and clinical factors in concert,
since causation of recurrence seems to be multifactorial with
multiple putative causal factors that interact over time.
The strengths of our study are that we were able to examine a
comprehensive set of predictors in a large representative sample
and used standardized instruments to determine diagnosis and
course. However, in interpreting the results of this study, one
should also be aware of its limitations. First, the respondents
treated in specialized mental health care were recently referred
and, as a consequence, this sample is not representative of the
entire population treated for MDD in specialized mental health
care, since patients with more severe, chronic or frequent recur-
ring MDD are probably underrepresented in the study. Conse-
quently, the difference in recurrence risk between primary care
and specialized mental health care could have been underesti-
mated. On the other hand, the percentage of remission between
respondents treated in primary care versus specialized mental
health care was not statistically different in our study which
suggests that the researched treatment cohorts are comparable in
this way. Secondly, subclinical residual symptoms, which are a
strong predictor of recurrence risk (Judd et al., 1998), could not be
included in the analysis because the data did not allow for such
precision. It is reasonable to assume that residual symptoms are
more common in respondents treated in specialized mental
health care than in respondents treated in primary care. Thirdly,
the follow-up duration of two years was relatively short if one
takes into account that respondents had to have been in remis-
sion ﬁrst. Although the average duration of follow-up was modest
at approximately 15 months, it is important to realise that the risk
of relapse is greatest in the ﬁrst year after recovery, and declines
rapidly thereafter. Therefore, it is unlikely that the conclusions of
the current paper would change if a longer follow-up period had
been available. Finally, our results may have been inﬂuenced by
the referral behaviour of general practitioners and may not be
generalizable to health systems that are very different from the
system in the Netherlands. However, the structure of the Dutch
health care system is comparable to that of several other
European countries in which the general practitioner serves as
the gatekeeper and referrals are needed for access to specialized
mental health care, and also the proportion of diagnosed persons
receiving mental health treatment, as well as the quality of care
received, is comparable to that in other high income countries
(US, UK, Spain, Belgium) (Alonso et al., 2004; Wang et al., 2007).5. Conclusion
In conclusion, the recurrence risk of MDD appeared to be
similar in specialized mental health care and primary care mean-
ing that the risk of recurrence in primary care is also considerable.
Respondents with a history of recurrent MDD and a family history
of MDD in ﬁrst-degree relatives had a shorter time to recurrence.
Patients with these risk factors should be closely monitored and
treatment strategies to prevent recurrence should be considered.
Our results also imply that prevention of recurrence of MDD is
advised for high-risk groups, not only in specialized mental health
care, but also in primary care. However, aside from pharmacolo-
gical treatment (Kaymaz et al., 2008), other programmes to
prevent recurrence, e.g. mindfulness-based cognitive therapy
(Piet and Hougaard, 2011) and cognitive therapy (Beshai et al.,
2011) are mainly carried out in specialized mental health care.
Therefore, general practitioners should refer patients, not only forspecialized treatment of depression, but also for prevention of
recurrence. Another possibility is to expand these programmes
beyond specialized mental health care. To improve the manage-
ment of recurrence prevention of MDD, collaborative care models
(Katon and Guico-Pabia, 2011), in which long term management
and communication between primary- and specialized mental
health care professionals are optimized across psychiatric
services, may be helpful.Role of funding source
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